Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody
14 Nov 2025
byDr. Shi-Feng Nyaw, Specialist in Clinical Oncology, Hong Kong; Prof. Tianqing Chu, Consultant at the Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai, China; Prof. Victor HF Lee, Clinical Professor, Department of Clinical Oncology, The University of Hong Kong
Lung cancer remains the most common cancer and a leading cause of cancer-related mortality, with improved but still suboptimal survival outcomes despite advances in treatment. At a recent symposium chaired by Dr Shi-Feng Nyaw, Specialist in Clinical Oncology, Hong Kong, Professor Tianqing Chu, Consultant at the Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai, China, highlighted how tislelizumab, a novel immunotherapy agent, differs from other anti–programmed death receptor 1 (PD-1) therapies. She presented efficacy and safety data for tislelizumab in both squamous and non-squamous non-small-cell lung cancer (NSCLC) from RATIONALE-307/304 and her routine clinical practice. Additionally, Professor Victor Lee, Clinical Professor at the Department of Clinical Oncology, The University of Hong Kong, shared real-world cases illustrating the clinical benefits of tislelizumab in NSCLC patients.
